Twinbeech Capital LP Nurix Therapeutics, Inc. Transaction History
Twinbeech Capital LP
- $5.52 Billion
- Q4 2024
A detailed history of Twinbeech Capital LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 29,776 shares of NRIX stock, worth $523,759. This represents 0.01% of its overall portfolio holdings.
Number of Shares
29,776
Previous 65,459
54.51%
Holding current value
$523,759
Previous $1.47 Million
61.88%
% of portfolio
0.01%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
179Shares Held
68.2MCall Options Held
304KPut Options Held
43.1K-
Black Rock Inc. New York, NY6.82MShares$120 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$76.4 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$73.7 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$68.3 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$63.1 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $829M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...